Group 1 - The company held its fourth board meeting on December 3, 2025, with all nine directors present, and the meeting was conducted in accordance with relevant laws and regulations [2][4]. - The board approved a proposal to apply for a comprehensive credit facility of up to 2.5 billion RMB from banks, which can be used repeatedly within a three-year authorization period [3][22]. - The board also approved a capital increase of 15 million RMB for Wanning Weiguang Plasma Co., Ltd. and 40 million RMB for Ankang Weiguang Plasma Station to enhance plasma collection capabilities [6][16]. Group 2 - The company plans to sign a "Blood Product Technology Cooperation Contract" with a partner, which includes a technology licensing fee of 12 million USD and a technology transfer service fee of 4 million USD, totaling approximately 113.21 million RMB [25][26]. - The contract aims to enhance the company's international brand influence and is expected to positively impact the company's operating results in the current and future years [48]. - The company will hold its fourth extraordinary shareholders' meeting on December 22, 2025, to discuss the proposals approved by the board [52][55].
深圳市卫光生物制品股份有限公司 第四届董事会第六次会议决议公告